Glecaprevir/Pibrentasvir Real-world Study in China

Sponsor
Tongji Hospital
Study ID
NCT03941821
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To evaluate the efficacy, adverse effect, short - and long-term outcomes of Glecaprevir/Pibrentasvir for the treatment of chronic hepatitis C (non-cirrhotic or compensatory cirrhosis)in China through a real-world study

Key Dates

Start date
Jun 30, 2019
Status verified
May 2019
Primary completion
Jun 30, 2021
Completion
Jun 30, 2022

Study Design

Enrollment
800 participants (estimated)

Arms

  • Arm: G/P treatment
    Chronic hepatitis C patients who will recieve Glecaprevir/Pibrentasvir treatment

Primary Outcome Measure

SVR 12 [ Time Frame: 12 weeks after Glecaprevir/Pibrentasvir treatments ]

Central Contacts